» Articles » PMID: 29205637

A Field Guide for Cancer Diagnostics Using Cell-free DNA: From Principles to Practice and Clinical Applications

Overview
Date 2017 Dec 6
PMID 29205637
Citations 86
Authors
Affiliations
Soon will be listed here.
Abstract

Recently, many genome-wide profiling studies provided insights into the molecular make-up of major cancer types. The deeper understanding of these genetic alterations and their functional consequences led to the discovery of novel therapeutic opportunities improving clinical management of cancer patients. While tissue-based molecular patient stratification is the gold standard for precision medicine, it has certain limitations: Tissue biopsies are invasive sampling procedures carrying the risk of complications and may not represent the entire tumor due to underlying genetic heterogeneity. In this context, complementary characterization of genetic information in the blood of cancer patients can serve as minimal-invasive 'liquid biopsy'. Fragments of circulating cell-free DNA (cfDNA) are released from tissues of healthy individuals as well as cancer patients. The fraction of cfDNA that is released from primary tumors or metastases (i.e. circulating tumor DNA, ctDNA) represents genetic aberrations in cancer cells, which are a potential source for diagnostic, prognostic, and predictive biomarkers. Recent studies have demonstrated technical feasibility and clinical applications including detection of drug targets and resistance mutations as well as longitudinal monitoring of tumors under therapy. To this end, a variety of pre-analytical procedures for blood processing, isolation and quantification of cfDNA are being employed and several analytical methods and technologies ranging from PCR-based single locus assays to genome-wide approaches are available, which considerably differ in sensitivity, specificity, and throughput. However, broad implementation of ctDNA analysis in daily clinical practice requires a thorough understanding of theoretical, technical, and biological concepts and necessitates standardization and validation of pre-analytical and analytical procedures across different technologies. Here, we review the pertinent literature and discuss the advantages and limitations of available methodologies and their potential applications in molecular diagnostics.

Citing Articles

Primary exploration of cell-free DNA in the plasma of patients with parathyroid neoplasms using next-generation sequencing.

Zheng Q, Cui M, Wang O, Chang X, Xiao J, Chen T Cancer Cell Int. 2025; 25(1):86.

PMID: 40075389 PMC: 11905564. DOI: 10.1186/s12935-025-03699-w.


ctDNA-based liquid biopsy reveals wider mutational profile with therapy resistance and metastasis susceptibility signatures in early-stage breast cancer patients.

Bharde A, Nadagouda S, Dongare M, Hariramani K, Basavalingegowda M, Haldar S J Liq Biopsy. 2025; 7:100284.

PMID: 40027235 PMC: 11863978. DOI: 10.1016/j.jlb.2024.100284.


Nanoparticle-assisted PCR: fundamentals, mechanisms, and forensic implications.

Vajpayee K, Paida V, Shukla R Int J Legal Med. 2025; .

PMID: 39841191 DOI: 10.1007/s00414-024-03402-0.


.

Med Genet. 2024; 34(1):53-68.

PMID: 38836013 PMC: 11110128. DOI: 10.1515/medgen-2022-2112.


Liquid Biopsies as Non-Invasive Tools for Mutation Profiling in Multiple Myeloma: Application Potential, Challenges, and Opportunities.

Heestermans R, Schots R, De Becker A, Van Riet I Int J Mol Sci. 2024; 25(10).

PMID: 38791247 PMC: 11121516. DOI: 10.3390/ijms25105208.